Temozolomide

Catalog No.S1237 Synonyms: CCRG81045, NSC 362856

Temozolomide Chemical Structure

Molecular Weight(MW): 194.15

Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.

Size Price Stock Quantity  
In DMSO USD 64 In stock
USD 70 In stock
USD 170 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Talazoparib and temozolomide exhibit marked combinatorial efficacy in PDXs. A, Western blot against MGMT by near-infrared imaging in PDX models.

    Clin Cancer Res, 2017, 23(2):523-535. Temozolomide purchased from Selleck.

    C57BL/6 mice were implanted in the striatum with citrine-GL26-Cherry-HMGB1, which were stably transfected to express the YFP citrine and HMGB1 fused to red fluorescent protein cherry. Fourteen days later, they were treated with saline, Ad-TK+Ad-Flt3L, or Ad-TK+Ad-Flt3L+TMZ (temozolomide). Five days after treatment, the cellular location of cherry-HMGB1 in these cells was assessed by confocal microscopy. Arrows, tumor cells (green) with cytoplasmic HMGB1 (red).

    Clin Cancer Res 2014 20(6), 1555-65. Temozolomide purchased from Selleck.

  • Viability of U87 cells(A) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs temozolomide (TMZ) and Bliss interaction index (B) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 400 μM TMZ(A) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-18.. Temozolomide purchased from Selleck.

    Cells were plated and 12 h after plating were treated with MMF (5 µM), FTY720 (50 nM), Temozolomide (TMZ, 3 µM) or in combination as indicated for 12 h. Cell viability was assessed by live / dead assay.

    Cancer Biol Ther, 2014, 15(12):1646-57. Temozolomide purchased from Selleck.

  • Establishment of TMZ-resistant (TR) GBM cell lines. a-d, Evaluation of temozolomide resistance in four glioblastoma cell lines. Cells were cultured in the presence of 5-600 μM of TMZ. A dose-dependent association between the survival rate of cells and TMZ concentration can be observed. Each group was cultured for 24 h in the presence of different concentrations of TMZ, followed by an evaluation of IC50 for TMZ inhibited growth in A172-TR/A172, U118-TR/U118, U251-TR/U251 and U87-TR/U87

    Neurochem Res, 2016, 41(12):3192-3205. Temozolomide purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Temozolomide is a monofunctional SN-1 alkylating agent that can modify nitrogen atoms in the DNA ring and the extracyclic oxygen group, chemically converted to MTIC and degrades to methyldiazonium cation, which transfers methyl groups to DNA at physiologic pH. A DNA damage inducer in L-1210 and L-1210/BCNU cells.
Features Methazolastone is a second-generation alkylating agent.
Targets
DNA replication [1]
(L-1210, L-1210/BCNU cells)
In vitro

Methazolastone causes formation of DNA alkali-labile sites which are present in similar amounts and repaired at a similar rate in L-1210 and L-1210/BCNU cell lines. In L-1210 but not in L-1210/BCNU methazolastone induces an arrest of cells in SL-G2-M phases.[1] Methazolastone sensitivity of both chemo-sensitive and resistant cells (D54-R and U87-R) is enhanced significantly under hyperoxia. Both Methazolastone and hyperoxia are associated with increased phosphorylation of ERK p44/42 MAPK (Erk1/2), but to a lesser extent in D54-R cells, suggesting that Erk1/2 activity may be involved in regulation of hyperoxia and Methazolastone-mediated cell death. Hyperoxia enhances Methazolastone toxicity in GBM cells by induction of apoptosis, possibly via MAPK-related pathways. [2] Methazolastone induces in monocytes the DNA damage response pathways ATM-Chk2 and ATR-Chk1 resulting in p53 activation. [3] Chronic Methazolastone exposure results in acquired Methazolastone-resistance and elevates miR-21 expression. [4] Methazolastone treatment triggers endoplasmic reticula (ER) stress with increased expression of GADD153 and GRP78 proteins, and deceases pro-caspase 12 protein. Methazolastone induces autophagy through mitochondrial damage- and ER stress-dependent mechanisms to protect glioma cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NHS5NXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO5XYY1QCCq M2OwdGlEPTB;MUO5MlIx6oDLwsJihKk2Njl3IN88US=> MVmyOVk3ODJ6Mh?=
KellyCis83 NWHIeJFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;JOFghcA>? MkG2TWM2OD1{NUGuNFDjiIoEsfMAjVE2Njd3IN88US=> NUHING9GOjV7NkCyPFI>
SK-N-AS M37LWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfFOFghcA>? NYOyRnVlUUN3ME2yNlcvPzEkgJpCtgKBkTJ{LkG1JO69VQ>? NVjTXZJYOjV7NkCyPFI>
SK-N-ASCis24 NWLl[nNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzBc5k{PDhiaB?= M1S3SmlEPTB;NEiwMlYx6oDLwsJihKkyODFwMUWg{txO M{jBTFI2QTZyMkiy
CHP-212 NX34cohJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fXPFQ5KGh? M4OxVmlEPTB;Nz65O-KBkcLz4pEJNE43QSEQvF2= M2nkTFI2QTZyMkiy
CHP-212Cis100 MkH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13kPVQ5KGh? Mk[3TWM2OD17LkW15qCKyrIkgJmwMlg5KM7:TR?= MmjiNlU6PjB{OEK=
U87  MoPwSpVv[3Srb36gRZN{[Xl? M4[2W|ExOCEQvF2= MlHGNlQuPzJiaB?= MnT1bY5lfWOnczDEZ3IyKGW6cILld5Nqd25? NFvZZ3ozPThyOEi2PC=>
LN229 MmK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2mzV|AuPTBizszN NGL2UmxKSzVyPUG2JO69VQ>? M1PsRlI2PzVyMkez
TR-LN229 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDRepUyOC13MDFOwG0> Mn7DTWM2OD15NzFOwG0> NVrwU5ZTOjV5NUCyO|M>
U87  NWK5dWxTSXCxcITvd4l{KEG|c3H5 NH\XU4wx6oDVMkCw5qCKyrWP MofkNlQhcA>? NX[3cGJP\W6qYX7j[ZMhS1FiaX7keYNm\CCjcH;weI9{cXN? M1jVbFI2PjhzNk[4
U251MG Mor5RZBweHSxc3nzJGF{e2G7 MkLZNVAxyqEQvF2= NVO3OXRWPDhiaB?= NHjsUVhRSlN? MX\pcoR2[2W|IHHwc5B1d3Orcx?= NYjCPII6OjV4OEC0OlQ>
U87MG MY\BdI9xfG:|aYOgRZN{[Xl? M37HcFExOMLizszN NIfueGM1QCCq M164NHBDWw>? NYHHeWhbcW6mdXPld{BieG:ydH;zbZM> MV6yOVY5ODR4NB?=
U87 NEXOfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLXOVAuOzVyIN88US=> NYX4WIxKPDkEoHlCpC=> M4HQ[YlvcGmkaYTzJINmdGxiZ4Lve5RpKHOuaXfoeIx6 NGjG[HkzPTV3NEKyNy=>
U118  NHzmPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G4OVUxNTN3MDFOwG0> NIjGNVU1QMLiaNMg NX:3W4hScW6qaXLpeJMh[2WubDDndo94fGhic3zp[4h1dHl? NHnBZ5MzPTV3NEKyNy=>
U87 NX\XRWxJTnWwY4Tpc44hSXO|YYm= MYqyOVAwOzVyIN88US=> Mn;5OFjDqGkEoB?= Mn;O[Y5p[W6lZYOgWG1ZNWmwZIXj[YQheC2SS1OtdIFvKGSnY4LlZZNm MlO2NlU2PTR{MkO=
U118  M2Hve2Z2dmO2aX;uJGF{e2G7 NULx[lNGOjVyL{O1NEDPxE1? NGrKfWM1QMLiaNMg NG\VPWNmdmijbnPld{BVVVhvaX7keYNm\CCyLWDLR{1x[W5iZHXjdoVie2V? NIjwbpMzPTV3NEKyNy=>
U87 NYTrT5MzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XNeVI2OC9|NUCg{txO Mlj4OFjDqGkEoB?= NHTKTHJqdmO{ZXHz[ZMhfGinIIDldoNmdnSjZ3Wgc4Yh[2WubIOgbY4hWyCjbnSgS|IwVcLiY3;0doVifGWmIIfpeIghXE2[ MUSyOVU2PDJ{Mx?=
A375 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4P5WFQ5yqCqwrC= MXrJR|UxRTJ4NTFOwG0> MUiyOVUzPDV3Mh?=
A2058 NIS1UphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojDOFjDqGkEoB?= MVvJR|UxRTF{IN88US=> MkLWNlU2OjR3NUK=
M238 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXi1R4tyPDkEoHlCpC=> NVnwbnR7UUN3ME20NEDPxE1? M2fh[lI2PTJ2NUWy
M249 NYLCe2ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX2wTFZ4PDkEoHlCpC=> MnfRTWM2OD1{NUSg{txO MWqyOVUzPDV3Mh?=
M21 M{m1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fmfFQ5yqCqwrC= MlPWTWM2OD1{MkGg{txO MkLxNlU2OjR3NUK=
U251 MnW1R5l1d3SxeHn0fUBCe3OjeR?= MkjlNlAh|ryPwrC= NXny[2EzPDkEoHlCpC=> M33jcpJm\HWlZXTzJJRp\SCyZYLj[Y51[WenczDv[kBkd2yxbnnld{Bnd3KvZXS= NE\6c5UzPTR|NEO4NS=>
LN229 MlXTR5l1d3SxeHn0fUBCe3OjeR?= NGjM[ZgzOCEQvF5CpC=> NXXMW2xvPDkEoHlCpC=> NV\5PY4{emWmdXPl[JMhfGinIIDldoNmdnSjZ3XzJI9nKGOxbH;ubYV{KG[xcn3l[C=> NFLTNlQzPTR|NEO4NS=>
U373MG-LUC NUHwbZFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFqwVG84OiCq NYD0WG5tUUN3ME62NFAh|ryP NULneZRqOjV2M{G5OVM>
U87  NUH2TlFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfDWHZDOjVvMkCwJO69VQ>? M3qwflQ5yqCqwrC= NUfzXnJOcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{\Gc|I2PDByN{S1
U251 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\oOWUzPS1{MECg{txO NWPTR|JPPDkEoHlCpC=> Ml7XbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWKyOVQxODd2NR?=
U251 NFnXfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vVWVExOC12MECg{txO NVG4dnFzPzJxOU[gbC=> M3;pU5Rp\SCjboTpMZBzd2yrZnXyZZRqfmViZX\m[YN1KGOjbjDi[UBmdmijbnPl[EBjgSCpb4PzfZBwdCCnbnjhcoNm\CEEoB?= MXuyOVM4PTJ5MR?=
U373 NV;WR5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXexNFAuPDByIN88US=> MmPpO|IwQTZiaB?= NHLCU451cGViYX70bU1xem:uaX\ldoF1cX[nIHXm[oVkfCClYX6gZoUh\W6qYX7j[YQh[nliZ3;zd5lxd2xiZX7oZY5k\WRiwrC= Ml7xNlU{PzV{N{G=
U343 NF;BVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexNFAuPDByIN88US=> M{jBUFczNzl4IHi= NXfqPG91fGinIHHueIkueHKxbHnm[ZJifGm4ZTDl[oZm[3RiY3HuJIJmKGWwaHHuZ4VlKGK7IHfvd5N6eG:uIHXubIFv[2WmINMg MVmyOVM4PTJ5MR?=
U87MG-luc2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LUVFExOC12MECg{txO MnTmO|IwQTZiaB?= MWL0bIUh[W62aT3wdo9tcW[ncnH0bZZmKGWoZnXjeEBk[W5iYnWg[Y5p[W6lZXSgZpkh\2:|c4nwc4wh\W6qYX7j[YQhyqB? NVnKWVJ{OjV|N{WyO|E>
U87 MV3GeY5kfGmxbjDBd5NigQ>? Mn\0NlAxKM7:TR?= NEHObo41QCCq MY\pcoNz\WG|ZYOgRnJESzNibWLORUBmgHC{ZYPzbY9v MW[yOVM{Pzd{MR?=
U251 NY\TZndpTnWwY4Tpc44hSXO|YYm= MXGyNFAh|ryP NWHkcFg6PDhiaB?= NF:y[IRqdmO{ZXHz[ZMhSlKFQ{OgcXJPSSCneIDy[ZN{cW:w NWDkSotsOjV|M{e3NlE>
A172 MnS0SpVv[3Srb36gRZN{[Xl? NVOzdmxzOjByIN88US=> M33CNVQ5KGh? M3fzO4lv[3KnYYPld{BDWkOFMzDtVm5CKGW6cILld5Nqd25? MmjSNlU{Ozd5MkG=
U251 NFfIT4tHfW6ldHnvckBCe3OjeR?= NIrvNpozODBizszN NXn2TGR6PDhiaB?= M{PldYlv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBDWkODMTygRnJESTJuIGLBSFUyKGGwZDDGRW5ETDJ? NGHRPJYzPTN|N{eyNS=>
A172 MVTGeY5kfGmxbjDBd5NigQ>? NVTuOJFlOjByIN88US=> MUK0PEBp MWfpcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ib3[gRnJESTFuIFLSR2EzNCCUQVS1NUBidmRiRlHOR2Qz NVfsbVk4OjV|M{e3NlE>
U87 NFT3SlFHfW6ldHnvckBCe3OjeR?= M3O2cVIxOCEQvF2= MVKyOE84Oi9zMkCgbC=> NUH6Nm9ncW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 MojENlU{Ozd5MkG=
U251 NHzGVJpHfW6ldHnvckBCe3OjeR?= NEnKVlEzODBizszN NVnrbo9TOjRxN{KvNVIxKGh? NXvDOI04cW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 M2j1N|I2OzN5N{Kx
A172 M4nQ[GZ2dmO2aX;uJGF{e2G7 NWj2c41kOjByIN88US=> NFjPTFUzPC95Mj:xNlAhcA>? NVmxZoRpcW6lcnXhd4V{KM7|SELBXEBnd2OrIH\vdo1ifGmxbjD0bY1mNWSncHXu[IVvfGy7 NXPleJZYOjV|M{e3NlE>
SNB19V M3XSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi5RndxPyCm MVPEUXNQ NIPhRlZIUTVyPUO1MlfDuTF{IN88US=> NWf5[XVHOjV{N{e0OFE>
SNB19M M4KxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PlVlch\A>? MmLVSG1UVw>? NILD[ZdIUTVyPUS2PU46yrF6ODFOwG0> MVKyOVI4PzR2MR?=
SNB19VR MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjDeW84KGR? MUjEUXNQ MU\HTVUxRTJ6MD6yxtEyQCEQvF2= MnnpNlUzPzd2NEG=
U373V MmHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHIO{Bl NHjZUGFFVVOR Ml25S2k2OD14OD6wxtE{OiEQvF2= MoDXNlUzPzd2NEG=
U373M MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYC3JIQ> NV:xVos3TE2VTx?= NH7hbZVIUTVyPUO2PE44yrF6NjFOwG0> NYf5VlZkOjV{N{e0OFE>
U373VR MkfoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYK3JIQ> Mnn5SG1UVw>? NISwenpIUTVyPUK4PE45yrF|MzFOwG0> MmGxNlUzPzd2NEG=
U87MG MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLxTVQ4KGR? NFfUWY1FVVOR NHX0PI5IUTVyPUO4MlPDuTJyIN88US=> NGfQVoUzPTJ5N{S0NS=>
HCT116 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW4VFM4KGR? Ml7PSG1UVw>? NGjQXnJIUTVyPUW3PU46yrF|MjFOwG0> NYnnb45vOjV{N{e0OFE>
DLD1 MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvmO{Bl Mnz3SG1UVw>? MWrHTVUxRTVyMT60xtE6OyEQvF2= MYGyOVI4PzR2MR?=
MRC5 MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3PPJY4KGR? MVLEUXNQ Mnz5S2k2OD12NEmuOOKyQCEQvF2= NHvIPVQzPTJ5N{S0NS=>
SNB19V  NGXRdZhHfW6ldHnvckBCe3OjeR?= MXOxNFAh|ryPwrDUUXo> MoTONE04OiCq NFHmXZZqdmO{ZXHz[ZMh|rOKMlHYJIV5eHKnc4Ppc44h[mW2d3XlckAyPiCjbnSgO|IhcA>? NFnFSW8zPTJ5N{S0NS=>
T98G  NWrSe4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[1M|ExNzF3IN88US=> M1uyR|I1yqCq MmjFbY5lfWOnczDj[YxtKGSnYYToJIRwe2VvZHXw[Y5l\W62bImgZYZ1\XJiY3;uZ49ucXSjboSteIVud3qxbH;tbYRmKHerdHigUnBmPi2SRGS= MXWyOVI3Ojl4MR?=
U251  NVezTWxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILpSFE2NzFyL{G1JO69VQ>? NF[5bW4zPMLiaB?= NGT3THVqdmS3Y3XzJINmdGxiZHXheIgh\G:|ZT3k[ZBmdmSnboTsfUBi\nSncjDjc45kd22rdHHueE11\W2xen;sc41q\GVid3n0bEBPWGV4LWDEWC=> MUWyOVI3Ojl4MR?=
T98G  MUDGeY5kfGmxbjDBd5NigQ>? NGP6eWgyPSEQvF2= NVfx[W9POjUEoHi= M1;ie4lv[3KnYYPld{BFVkFvZoLh[41mdnSjdHnvckBqdiCQUHW2MXBFXCC2cnXheIVlKGeuaX;tZUBk\Wyucx?= MmjqNlUzPjJ7NkG=
U251  MVzGeY5kfGmxbjDBd5NigQ>? MonSNVUh|ryP MX6yOOKhcA>? MnvIbY5kemWjc3XzJGRPSS2ocnHncYVvfGG2aX;uJIlvKE6SZU[tVGRVKHS{ZXH0[YQh\2yrb33hJINmdGy| NX3yW21WOjV{NkK5OlE>
U-87 MG M2ry[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVH1fpplPzJiaB?= NEnQSIlKSzVyPUCuPVMhdU4EoB?= NY\abWF5OjV{NEWzN|I>
U-118 MG MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT2PJRKPzJiaB?= NVfpeZVIUUN3ME2xMlA2KG2PwrC= MonZNlUzPDV|M{K=
U87 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvjdphLOjRiaB?= MYnJR|UxRTJ4MD6zOEDPxE4EoB?= MV[yOVE4OzJ|Mx?=
U87 GSLCs M1nYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\XbXFZOjRiaB?= M2ji[GlEPTB;N{[2MlEyKM7:TdMg MVOyOVE4OzJ|Mx?=
U87MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[4doNLPzJiaB?= M3XrdGlEPTB;MUWuOlI2KM7:TdMg NWPSUVZROjVyNUC5NVU>
U251 M1TDc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHNNVAxNTRyMDFOwG0> MV[0PEBp MVPEUXNQ MXTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXjqWnQ5OjR4MkO3N|Y>
U87 NYf1OFY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1P3UFExOC12MECg{txO M{LkNFQ5KGh? M1zOS2ROW09? NGn4RppqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIHSfXQzPDZ{M{ezOi=>
MDA-MB-231-br M2PDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3ZdpAxNTFyIN88US=> NITHN4w1QCCq MnX6SG1UVw>? NGHYSmRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIqzTXczPDZ{M{ezOi=>
HCC-1937 Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X0NlAuOzByIN88US=> NF:0epY1QCCq NHi4WI5FVVOR NHjqVmtqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWDzWmRXOjR4MkO3N|Y>
MDA-MB-231 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XJT|AuPDBizszN NEK3SHE1QCCq M{HIU2ROW09? M37tRolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NGnnbGgzPDZ{M{ezOi=>
MDA-MB-468 NXPIVmZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljvNE02ODBizszN MUG0PEBp NGj2eJBFVVOR MnfDbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NXf6TIJkOjR4MkO3N|Y>
T47D NHLQNFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PBdFAuOTByIN88US=> MVK0PEBp NULMcoFpTE2VTx?= MlPWbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NV;WU|lpOjR4MkO3N|Y>
MCF7 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHsRplOOC1zMECwJO69VQ>? MXe0PEBp NUn2N3NkTE2VTx?= M{\INolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYXp[ZR[OjR4MkO3N|Y>
Hs683 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYmwMVExODBizszN NGHhNZA6PiCq MW\JR|UxRTF{OD65JO69VQ>? NVnlc5pROjR2OUW5NFc>
U87 M4f2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVGwMVExODBizszN NV61NJpFQTZiaB?= M1;MT2lEPTB;MUiuOFUh|ryP MlvkNlQ1QTV7MEe=
LNZ308 NWLjOHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYewMVExODBizszN MX[5OkBp MXPJR|UxRTN{Nj63JO69VQ>? NHfRdWgzPDR7NUmwOy=>
U87 MYTBdI9xfG:|aYOgRZN{[Xl? MUmxNFAh|ryP MnPLOFghcA>? NULNRZQ{TE2VTx?= MmfYbY5kemWjc3XzJJRp\SClYYPwZZNmNTNxNzDhZ5Rqfmm2eR?= NFfj[lAzPDR6MUW4Oi=>
U251  NYfJUHF[SXCxcITvd4l{KEG|c3H5 NWnGNlhoOTByIN88US=> MVq0PEBp MmO5SG1UVw>? NE\BWo9qdmO{ZXHz[ZMhfGinIHPhd5Bie2VvMz:3JIFkfGm4aYT5 NELuW5QzPDR6MUW4Oi=>
U251 NH3OSnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfQNlQhcA>? MVnJR|UxRTh4LkK55qCKyrIkgJmxMlU5KM7:TR?= NWfMdIgzOjR|Mk[5OVQ>
U251 NHzJdVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTB[o81QCCq NIeyfZRKSzVyPUe1MlM16oDLwsJihKkyNjB{IN88US=> NHfNe3kzPDN{Nkm1OC=>
U251 NIe3PFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV63NkBp NYnkVldKUUN3ME23Nk41OuLCidMx5qCKOS52NTFOwG0> MXWyOFMzPjl3NB?=
U251 M{DyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L0clk3KGh? MlexTWM2OD14OT64NwKBkcLz4pEJN{4xPCEQvF2= NX7aN5dGOjR|Mk[5OVQ>
T98G MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXyNE04PTBizszN Ml3NO|IwQTZiaB?= Mm\obY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M3[1cVI1OzJ2MEiw
U251-MG NEnQZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LiR|AuQDByIN88US=> MljFO|IhcA>? M3fxd4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZTDk[ZBmdmSnboSgcYFvdmW{ M4j4[VI1ODl|NkOw
D54-MG NX\BUlY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUKwMVgxOCEQvF2= MX23NkBp NWS3XoxscW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NWrkNnZ3OjRyOUO2N|A>
SHG-44 MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlf5NVAuOjByIN88US=> NInyOmI6PiCq NHTFN|ZKSzVyPUmuO|MhyrFiMj6xNkDPxE1? M{TUSVI1ODZ3NU[5
U373  M4q5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfHZnMyOC1{MECg{txO MX65OkBp NXrCVYw2UUN3ME2xNE4yOyEEsTCxMlAzKM7:TR?= NXW1SXZLOjRyNkW1Olk>
HT-29  MkfKSpVv[3Srb36gRZN{[Xl? NFfIUZA2ODBizszN M3fXT|I1NzR6IHi= M4PyS4VvcGGwY3XzJJRp\SCuZY\lcJMhd2ZizsOtTFJCYMLi Mn;lNlQxOzhyNki=
PC-3  MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDINE0zPSEQvF2= NYm3PVNNPDhiaB?= NGLnSFVqdmirYnn0d{Bk\WyuIHfyc5d1cCC5aHnjbEBk[W5iYnWgdI91\W62aXH0[YQh[nlibInjc5BmdmV? NHrs[ZAzOzd2NkmzOC=>
PC-3  M3n3N2Fxd3C2b4Ppd{BCe3OjeR?= MU[yOUDPxE1? NYSzOXZLPDhiaB?= NUSwSIV6cW6mdXPld{BieG:ydH;zbZMhf2irY3igZ4FvKGKnIIDveIVvfGmjdHXkJIJ6KGy7Y3;w[Y5m MkXjNlM4PDZ7M{S=
T98G MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHOXY82OC12MECg{txO Mnn2NVQ1KGh? MYHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M4DTOFI{PzF3NEm5
U87-MG M4HQW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{CwNlExOCEEtV2= MnTFO|IhcA>? MVTpcohq[mm2czDj[YxtKGe{b4f0bEB4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgS3RD M1PyfVI{Pjl4N{i4
U251-MG MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUOxNFAhyrWP MWG3NkBp MlHUbY5pcWKrdIOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHXubIFv[2WmIHL5JGdVSg>? MmDwNlM3QTZ5OEi=
LNT-229 NUjVVXRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:zMVExOCEQvF2= MUCyOEBp NUTEV2czcW6qaXLpeJMh[2yxbn;n[Y5q[yC|dYL2bZZidCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M4X3RlI{PjZ5NkOy
T98G MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXTNVAuPzByIN88US=> MVOyOEBp MWHpcohq[mm2czDjcI9vd2enbnnjJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmLpNlM3Pjd4M{K=
U87  MXvGeY5kfGmxbjDBd5NigQ>? M{nsWlExOCEEtV2= MX[zJIg> MlTU[YxmfmG2ZYOgeIhmKGyndnXsd{Bw\iCyQ3jrNUBidmRicFPob|I> NW\0XWxjOjN4Nke0Olk>
HCT116 M4TlRmZ2dmO2aX;uJGF{e2G7 MXOxNFAhyrWP NYHJO5J7OyCq NF;jS2NqdmS3Y3XzJJRp\SCFaHuxJHBpd3OyaH;yfYxifGmxbh?= NVSwSotyOjN4Nke0Olk>
HCT3-6 NFjVXnZHfW6ldHnvckBCe3OjeR?= NWfTOopMOTByINM1US=> NWn5coZwOyCq MnzvbY5lfWOnczD0bIUhS2itMTDQbI9{eGixconsZZRqd25? NFPNT2IzOzZ4N{S2PS=>
U-87  NY\zcoEzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfCOJUxNTRyIN88US=> NG\2[lQyOiCm MknTbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1PuNlI{PjR3N{K5
U-87  MoLIRZBweHSxc3nzJGF{e2G7 M1rDVlAuPDBizszN MlnHN{83KGR? NILHfoJqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? Mo\VNlM3PDV5Mkm=
U-87  MknpSpVv[3Srb36gRZN{[Xl? NILZSXAxNTRyIN88US=> NGOxU5I{NzZiZB?= NHjPTWpqdmS3Y3XzJIF2fG:yaHHnfUBqdiCkb4ToJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M1fifVI{PjR3N{K5
GB-SCC010 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HJdVQh\A>? NFTqXZNKSzVyPUKyOkDPxE1? NGn0SlIzOzZzMke1OS=>
GB-SCC026 MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDqOEBl MULJR|UxRTV|LkGg{txO MV[yN|YyOjd3NR?=
GB-SCC028 NFiwWHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUC0JIQ> MmfZTWM2OD1zNkeg{txO M2\sXVI{PjF{N{W1
U87 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELRV4s1KGR? M2nacWlEPTB;NEWuNkDPxE1? NUjhPW9EOjN4MUK3OVU>
U87 stem cell MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi0JIQ> M4PafWlEPTB;Nk[uO{DPxE1? M1O0SlI{PjF{N{W1

... Click to View More Cell Line Experimental Data

In vivo After a daily i.p. dose of 40 mg/kg for 5 consecutive days (days 1-5 after tumor transplant), methazolastone increases life-span by 86% in L-1210 and 22% in L-1210/BCNU. In L-1210/BCNU no effect is seen after 100 μM or 200 μM treatment; only 400 μM methazolastone produced an accumulation of cells in premitotic phase but much less than in L-1210. In L-1210/BCNU the maximum accumulation of cells in SL-G2-M is, after 48 hours-72 hours, approximately 30% as compared to 23% in untreated cells. Cells accumulates in SL-G2-M occurred too when L- 1210 leukemia-bearing mice are treated i.v. with methazola stone (40 mg/kg). No such effect is seen on L-1210/BCNU cells from mice given the same drug dose. [1]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: L-1210 and L-1210/BCNU cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: l hours
  • Method:

    L-1210 and L-1210/BCNU cells are seeded at 0.2 × 104 cells/mL and incubated for 24 hours. The cultures are treated with Methazolastone for l hours at 37oC, then washed twice in PBS by centrifugation and resuspended in fresh medium. Controls and treated samples are diluted in fresh medium 1:4 at 48 hours and 1:2 at 96 hours. Using these dilutions cell concentrations throughout the experiments are between 3 × 105 and 8 × 105/mL. Control growth is logarithmic in this range.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: DBA/2 mice with L-1210 and L-1210/BCNU cells
  • Formulation: 95% ethanol
  • Dosages: 40 mg/kg
  • Administration: Administered via i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (195.72 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+30% PEG 300+ddH2O
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 194.15
Formula

C6H6N6O2

CAS No. 85622-93-1
Storage powder
Synonyms CCRG81045, NSC 362856

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02977780 Recruiting Glioblastoma Dana-Farber Cancer Institute|Eli Lilly and Company|Celgene|Puma Biotechnology, Inc.|Accelerate Brain Cancer Cure February 9, 2017 Phase 2
NCT02689336 Recruiting Glioma|Rhabdomyosarcoma|Osteosarcoma|Medulloblastoma|Neuroectodermal Tumor|Ependymoma|Ewings Sarcoma|Wilms Tumor Washington University School of Medicine August 6, 2016 Phase 2
NCT02455557 Recruiting Glioblastoma|Gliosarcoma Roswell Park Cancer Institute|National Cancer Institute (NCI) May 5, 2015 Phase 2
NCT01473901 Active, not recruiting Glioblastoma Novartis Pharmaceuticals|Novartis December 30, 2011 Phase 1
NCT03018288 Not yet recruiting Glioblastoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 3, 2017 Phase 2
NCT02766270 Recruiting Grade II/III Glioma Beijing Tiantan Hospital|Beijing Neurosurgical Institute|Beijing Shijitan Hospital September 26, 2016 Early Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Related Antibodies

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Temozolomide | Temozolomide ic50 | Temozolomide price | Temozolomide cost | Temozolomide solubility dmso | Temozolomide purchase | Temozolomide manufacturer | Temozolomide research buy | Temozolomide order | Temozolomide mouse | Temozolomide chemical structure | Temozolomide mw | Temozolomide molecular weight | Temozolomide datasheet | Temozolomide supplier | Temozolomide in vitro | Temozolomide cell line | Temozolomide concentration | Temozolomide nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID